BI 764532
DLL3/CD3 T-cell engager
Search
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager: DLL3/CD3 T-cell engager
Respimat media
Generalized pustular psoriasis: Unmet needs
Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the impact of living with GPP including unseen challenges and future management.
1885-1948: Innovative beginnings
The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products
DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
Fencovis®
Indicated for infectious diseases in cattle
Boehringer Ingelheim and GST prepared bring innovation to equine market
Boehringer Ingelheim and Global Stem Cell Technology are prepared to bring groundbreaking innovation to equine market
Uncommon_Mutations_Database
New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
COVID-19 Material donations in Germany
Upstream and Downstream Processing | Bioxcellence | Boehringer Ingelheim
Experience our exceptional expertise in upstream & downstream biopharmaceutical processing, utilizing mammalian cell cultures & microbial organisms.
BULTAVO 3
Indicated for bluetongue disease serotype 3 in sheep and cattle
CD137/FAP agonist
CD137/FAP agonist
B7-H6/CD3 T-Cell Engager
B7-H6/CD3 T-Cell Engager
KISIMA® cancer vaccine
KISIMA® Cancer Vaccine
Ethical Business Practices
Suppliers shall conduct their business in an ethical manner and act with integrity.
Boehringer Ingelheim advances SIRP immune-oncology program
Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
VSV-GP
VSV-GP
Supporting local communities by offsetting carbon emissions
Boehringer Ingelheim partially offsets its carbon emissions by partnering with ClimateSeed
Our-position
Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial
Option to Acquire Trutino Biosciences
Option to Acquire Trutino Biosciences
Patient Organizations
Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
Reimagining digital healthcare worldwide
How does our digital lab BI X innovate in Ingelheim and Shanghai? Read about success stories based on different ideation processes
Covid Global Support Programm
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program